Evidence map›Paper›PMID 39747716›Full record

ArticleJournal of neuro-oncology2025

Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.

Sanghee Lim, Nathan H Clarke, Sara L Maloney, Ugur T Sener, Samantha J Caron, Sani H Kizilbash, Jian L Campian, Bryan J Neth, Ivan D Carabenciov, Joon Uhm and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sanghee LimDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Nathan H ClarkeDivision of Neuro-Oncology, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
Sara L MaloneyDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Ugur T SenerDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Samantha J CaronDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Sani H KizilbashDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Jian L CampianDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Bryan J NethDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Ivan D CarabenciovDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Joon UhmDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Michael W RuffDivision of Neuro-Oncology, Department of Neurology, Mayo Clinic, Rochester, MN, USA. ruff.michael@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBevacizumab, an anti-VEGF monoclonal antibody, has become a mainstay therapeutic in the management of malignant glioma. It is unknown if the risk of intracranial hemorrhage (ICH), a major complication associated with bevacizumab use, is dose-dependent.

methodsThis was a single institution retrospective analysis of patients treated with bevacizumab for the management of gliomas between 2009 and 2022. Incidence rates of ICH between patients receiving low-dose (< 5 mg/kg/week) and conventional-dose (5 mg/kg/week) bevacizumab regimens were compared via competing risk analysis over time. We evaluated post-progression survival (PPS) as a secondary outcome using multivariate Cox regression.

resultsOne hundred and seventy-three patients were identified (low-dose group, n = 51, conventional-dose group, n = 122) for inclusion in our analysis. Cumulative incidence rates of all cases of ICH and clinically symptomatic cases of ICH were higher in the conventional-dose (17.2% for all cases, 13.7% for symptomatic) relative to the low-dose group (3.9% for all cases, 2.0% for symptomatic); p-value 0.0296 for all cases, p-value 0.0274 for symptomatic cases. On multivariate Fine-Gray regression, conventional-dose bevacizumab therapy remained significantly associated with increased risk for symptomatic ICH (SHR 8.0560; p-value 0.0442). No difference in PPS was observed between the low-dose versus conventional-dose groups.

conclusionsConventional-dose bevacizumab therapy (5 mg/kg/week) is associated with increased incidence of ICH in patients with malignant glioma compared to lower dose bevacizumab (< 5 mg/kg/week) in this single center retrospective cohort. No difference in PPS was observed between the low-dose versus conventional-dose groups.

Indexed as

Angiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabBrain NeoplasmsGliomaIntracranial HemorrhagesAdultAgedDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPrognosisAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabAntiangiogenic therapyAnti-VEGF therapyBevacizumabGlioblastomaGliomaIntracranial hemorrhage

Identifiers

PMID39747716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.